Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis

摘要

Background The 52-week safety and efficacy of adalimumab in Japanese patients with moderately to severely active ulcerative colitis were demonstrated in a placebo-controlled phase 2/3 trial. Data from patients who enrolled in the open-label extension study are presented.